logo
Plus   Neg
Share
Email

Pfizer Says EMA Accepted Marketing Authorization Application For Growth Hormone Somatrogon

Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022.

The company said somatrogon is a long-acting recombinant human growth hormone administered once-weekly for the treatment of pediatric patients with growth hormone deficiency.

The somatrogon Phase 3 trial enrolled 224 pediatric patients in a randomized, open-label, active-controlled study in over 20 countries.

The US Food and Drug Administration accepted the initial Biologics License Application in January 2021 and a New Drug Application was submitted to PMDA in Japan for somatrogon in January.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT